{
    "clinical_study": {
        "@rank": "143081", 
        "arm_group": {
            "arm_group_label": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
            "arm_group_type": "Active Comparator", 
            "description": "(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg )bid for the next 5 days : Sequential therapy 1\n(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2\n(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg )bid for 10 days : Concomitant therapy 1\n(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2"
        }, 
        "brief_summary": {
            "textblock": "Comparison of the eradications rates of sequential therapy versus concomitant therapy of\n      treatment of Helicobacter pylori infection in Korea.\n\n      single center, randomized trial\n\n        1. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg)\n           bid for 10 days\n\n        2. (pantoprazole 40 mg + amoxicillin 1.0g + clarithromycin 500 mg + metronidazole 500 mg)\n           bid for 14 days\n\n        3. (pantoprazole 40 mg + amoxicillin 1.0g) bid for 5 days and subsequent  pantoprazole\n           40mg + clarithromycin 500 mg + metronidazole 500 mg) bid for 5 days\n\n        4. (pantoprazole 40 mg + amoxicillin 1.0g) bid for 7 days and subsequent  pantoprazole\n           40mg + clarithromycin 500 mg + metronidazole 500 mg) bid for 7 days\n\n      1st endpoint : Helicobacter pylori eradication rates (intention to treatment, per-protocol)\n      2nd endpoint : adverse event(nausea, vomiting, dizziness, bitter sense) drug compliance"
        }, 
        "brief_title": "Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Helicobacter Pylori Infection", 
        "condition_browse": {
            "mesh_term": "Helicobacter Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20~70 patients\n\n          -  agreement of informed consent\n\n          -  H.pylori positive (biopsy, CLO)\n\n          -  Peptic ulcer disease, mucosa associated lymphoid tissue lymphoma, Post endoscopic\n             submucosal dissection status due to early gastric cancer\n\n        Exclusion Criteria:\n\n          -  H.pylori eradication history\n\n          -  severe hepatic, renal, cardiac failure\n\n          -  pregnancy, participant of other study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "248", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108184", 
            "org_study_id": "PSungmin"
        }, 
        "intervention": [
            {
                "arm_group_label": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "description": "(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1", 
                "intervention_name": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "description": "(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2", 
                "intervention_name": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "description": "(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1", 
                "intervention_name": "pantoprazole, amoxicillin, clarithromycin, metronidzole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "description": "(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2", 
                "intervention_name": "pantoprazole, amoxicillin, clarithromycin, metronidazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Clarithromycin", 
                "Metronidazole", 
                "Pantoprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "helicobacter eradication rates", 
        "lastchanged_date": "May 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Sungmin Park"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of", 
                    "state": "Bupyung", 
                    "zip": "KSXX0009"
                }, 
                "name": "Incheon St.Mary hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea", 
        "overall_contact": {
            "email": "danson2000@hanmail.net", 
            "last_name": "Sung min Park", 
            "phone": "082-032-280-5052"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Republic of Korea : KFDA", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess Helicobacter pylori eradication rates", 
            "measure": "Comparison of the eradications rates of sequential therapy versus concomitant therapy of treatment of Helicobacter pylori infection in Korea.", 
            "safety_issue": "No", 
            "time_frame": "required  average 10 weeks to assess Helicobacter pylori eradication rate from 1st visit"
        }, 
        "reference": {
            "PMID": "23305083", 
            "citation": "Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter. 2013 Jun;18(3):180-6. doi: 10.1111/hel.12034. Epub 2013 Jan 11."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108184"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Incheon St.Mary's Hospital", 
            "investigator_full_name": "Sung min, Park", 
            "investigator_title": "fellow", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "24073312", 
            "citation": "Kim JS, Kim BW, Ham JH, Park HW, Kim YK, Lee MY, Ji JS, Lee BI, Choi H. Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis. Gut Liver. 2013 Sep;7(5):546-51. doi: 10.5009/gnl.2013.7.5.546. Epub 2013 Aug 14."
        }, 
        "source": "Incheon St.Mary's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incheon St.Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}